Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of the new somatostatin analogue SMS 201-995 on exogenously used insulin

  • 12 Accesses

  • 1 Citations

Abstract

Somatostatin and somatostatin analogues are inhibitors of insulin,glucagon, and growth hormone secretion. However, it has not been determined whether it is somatostatin or its analogues which affect these hormones when used concomitantly. The effect of the somatostatin analogue SMS 201-995 on exogenously infused insulin was observed in ten healthy volunteers. The study was carried out on two occasions with at least a 1-week interval. Each subject was infused with saline throughout the study and insulin at a rate of 40 mU/kg per hour between 60–160 min of the study (step A) or SMS 201-995 in a 75 μg IV bolus following at a rate of 75 μg/h for 160 min and insulin at the same rate and duration (step B). Hyper-insulinemia and SMS 201-995 significantly suppressed C-peptide secretion, but the degree of C-peptide suppression was greater in the SMS 201-995 infused step than in the insulin-only infused step. Blood glucose levels decreased markedly throughout the infusion of insulin with or without SMS 201-995. In step B, the decrease in blood glucose was greater than in step A. Insulin levels in step B increased to higher levels than in step A (from 81.1 ± 7.7 to 363.9 ± 22.7 mmol/l and from 82.7 ± 8.6 to 229.0 ± 23.4 mmol/l, respectively). These results show that SMS 201-995 increases the level of exogenously infused insulin. This is probably due to the impaired clearance of exogenous insulin.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Ipp E, Sinai Y, Bar-oz B, Nesher R, Cerasi E (1987) Somatostatin impairs clearence of exogenous insulin in humans. Diabetes 36:673–677

  2. 2.

    Kollind M, Moberg E, Lins PE, Adamson U (1990) Exogenous somatostatin raises plasma insulin levels in patients with insulin dependent diabetes mellitus. Horm Metab Res 22:581–583

  3. 3.

    Kutz K, Nuesch E, Rosenthaler J (1986) Pharmacokinetics of SMS 201–995 in healthy subjects. Scand J Gastroenterol 21 [Suppl 119]:65–72

  4. 4.

    Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E (1985) Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Eng J Med 313:1576–1580

  5. 5.

    Rabkin R, Ryan MP, Duckworth WC (1984) The renal metabolism of insulin (review). Diabetologia 27:351–357

  6. 6.

    Scheen AJ, Gillet J, Rosenthaler J, Guiot J, Henrivaux P, Jandrain B, Lefebvre PJ (1989) Sandostatin, a new analog of somatostatin, reduces the metabolic changes induced by nocturnal interruption of continous subcutaneous insulin infusion in type 1 (insulin dependent) diabetic patients. Diabetologia 32:801–809

  7. 7.

    Serrana Rios M, Navascues I, Saban J, Ordonez A, Sevilla F, del Pozo E (1986) Somatostatin analog SMS 201–995 and insulin needs in insulin dependent diabetic patients studied by means of an artificial pancreas. J Clin Endocrinol Metab 63:1071–1074

  8. 8.

    Spinas GA, Bock A, Keller U (1985) Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin analogue (SMS 201–995) in insulin dependent diabetes mellitus. Diabetes Care 8:429–435

  9. 9.

    Vora JP, Owens DR, Luzio S, Atiea J, Ryder R, Hayes TM (1987) Renal response to intravenous somatostatin in insulin dependent diabetic patients and normal subjects. J Clin Endocrinol Metab 64:975–979

Download references

Author information

Additional information

Correspondence to: M. Bayraktar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bayraktar, M., Usman, A. & Koray, Z. Effect of the new somatostatin analogue SMS 201-995 on exogenously used insulin. Clin Investig 72, 669–672 (1994). https://doi.org/10.1007/BF00212984

Download citation

Key words

  • SMS 201-995
  • Exogenous insulin
  • C-peptide